Aridis Pharmaceuticals Inc. (ARDS)
| Market Cap | 69.35M |
| Revenue (ttm) | 1,000,000 |
| Net Income (ttm) | -22.16M |
| Shares Out | 8.92M |
| EPS (ttm) | -2.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $6.89 |
| Previous Close | $7.01 |
| Change ($) | -0.12 |
| Change (%) | -1.71% |
| Day's Open | 7.25 |
| Day's Range | 6.89 - 7.29 |
| Day's Volume | 18,112 |
| 52-Week Range | 4.34 - 8.97 |
SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
SAN JOSE, Calif., Oct. 19, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-...
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.
SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.
SAN JOSE, Calif., Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.
SAN JOSE, Calif., June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week.
SAN JOSE, Calif., June 22, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
SAN JOSE, Calif., June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...
As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals
Shares of the thinly traded, micro-cap biotech Aridis Pharmaceuticals Inc (NASDAQ: ARDS) were retreating to a one-week low Tuesday morning.
Shares of Aridis Pharmaceuticals Inc. plunged 27% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a phase 2 trial of its treatment of ventilator-associated pn...
Aridis Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
About ARDS
Aridis Pharmaceuticals, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-... [Read more...]
| Industry Biotechnology | IPO Date Aug 10, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol ARDS |
Financial Performance
In 2019, ARDS's revenue was $1.02 million, a decrease of -62.93% compared to the previous year's $2.76 million. Losses were -$29.68 million, 34.3% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 17.20, which is an increase of 149.64% from the latest price.